Abstract P1-16-01: Efficacy of endocrine- versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA)

Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimo Cristofanilli(Cornell University), Grazia Arpino(University of Naples Federico II), Sergio Venturini(University of Turin), Thomas Bachelot(Centre Léon Bérard), Massimo Milani(University of Padua), Mario Giuliano(Regione Campania), Carla Rognoni(Bocconi University), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Sabino De Placido, Antonio Giordano(Harvard University), Barbara Pistilli(Institut Gustave Roussy)
Cancer Research
February 15, 2019
10.1158/1538-7445.sabcs18-p1-16-01
Cited by 2

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724